Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Bibliographic Details
Title:	Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling
Authors:	Alsadhan, Anfal A. ^, Cheung, Jean ^, Gulrajani, Michael ^, Cook, Erika M. ^, Pittaluga, Stefania, Davies-Hill, Theresa ^, Izumi, Raquel, Sun, Clare C., Covey, Todd ^, Wiestner, Adrian, Herman, Sarah E.M. ^*
Source:	In Blood 29 November 2018 132 Supplement 1:4401-4401
Database:	ScienceDirect